Loading stock…

Fresenius Medical Care AG (FME) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Fresenius Medical Care AG

FMEMarket cap $11BPrice $41.9

Country🇩🇪Germany

SectorHealthcare

IndustryHealthcare Services

Runs dialysis clinics and makes kidney-care machines for over 300,000 patients worldwide. It's the biggest player in a market where demand keeps rising as diabetes and hypertension fuel kidney failure globally.

In Bastion Portfolios?

52W Return-19%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+4%4

Revenue Forecast

Rev CAGR (1y)+39%9

Rev CAGR (3y)+2%2

Rev CAGR (5y)+3%2

Earnings Forecast

EPS Growth Y+1+19%8

EPS Growth Y+2-1%3

EPS Growth Y+3+10%7

Quality

Margins

EBIT Margin10%4

Net Income Margin5%4

Free Cash Flow Margin9%5

Debt

Net Debt/EBITDA3.03

Efficiency

ROE7%3

ROA4%5

Earnings Stability55

GEAR+AVERAGE52

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)109

P/E Ratio (Forward 3y)89

P/BV0.810

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd510

Yield

Free Cash Flow Yield18.0%10

Dividend Yield4.0%8

Momentum

Short term

1 month return-4%6

3 month return-11%3

YTD return-5%4

Mid term

Price vs 52wHigh81%6

1 year return-17%3

Long term

3 year return+6%3

5 year return-29%2

Risk Shield

Price Risk

Beta0.29

Volatility30%7

Free Cash Flow

Free Cash Flow Margin9%5

Free Cash Flow Yield18.0%10

Quality

ROCE8%5

Earnings Stability55

Net Debt/EBITDA3.03

02Growth

Is it actually growing, and how fast?

FMEFresenius Medical Care

Revenue FY25$23.1B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+4%4

Revenue, next 1Y+39%9

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+19%8

EPS growth, FY27E-1%3

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 10%/yr vs revenue 2%/yr), so margins should widen.

WATCH

Revenue is set to grow 2%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 4%/yr over the last 3 years and is set to keep growing around 2%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

Growth is a weak point here. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

FMEFresenius Medical Care

Total return Current−38.2%

Price return Current−50.5%

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-11%3

YTD return-5%4

MID & LONG-TERM▾SCORE

% of 52-week high81%6

1-year return-17%3

3-year return+6%3

5-year return-29%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 17% over the past year, now 19% below its 52-week high. That is right in line with the market.

Returns sit at the market level over the past month (-4%) and so far this year (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+6.2% over three years and -29% over five), behind 70% of the market.

The stock is underperforming over three months (-11%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Fresenius Medical. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

FMEFresenius Medical Care

Revenue FY25$23.1B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+4%4

Revenue, next 1Y+39%9

Revenue, next 3Y, CAGR+2%2

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+19%8

EPS growth, FY27E-1%3

EPS growth, FY28E+10%7

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 10%/yr vs revenue 2%/yr), so margins should widen.

WATCH

Revenue is set to grow 2%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 4%/yr over the last 3 years and is set to keep growing around 2%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

BOTTOM LINE

Margin Expander

Growth is a weak point here. The one thing to watch: the five-year outlook is thin.

03Price Momentum

Is the market behind it right now?

FMEFresenius Medical Care

Total return Current−38.2%

Price return Current−50.5%

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-4%6

3-month return-11%3

YTD return-5%4

MID & LONG-TERM▾SCORE

% of 52-week high81%6

1-year return-17%3

3-year return+6%3

5-year return-29%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 17% over the past year, now 19% below its 52-week high. That is right in line with the market.

Returns sit at the market level over the past month (-4%) and so far this year (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+6.2% over three years and -29% over five), behind 70% of the market.

The stock is underperforming over three months (-11%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Fresenius Medical. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community